+Follow
Yeocs818
No personal profile
0
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Yeocs818
09-17
Good or bad for Nage
Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4136371379244552","uuid":"4136371379244552","gmtCreate":1673268284109,"gmtModify":1673400156257,"name":"Yeocs818","pinyin":"yeocs818","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":608775404020544,"gmtCreate":1789653585918,"gmtModify":1789654069293,"author":{"id":"4136371379244552","authorId":"4136371379244552","name":"Yeocs818","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4136371379244552","authorIdStr":"4136371379244552"},"themes":[],"title":"","htmlText":"Good or bad for Nage","listText":"Good or bad for Nage","text":"Good or bad for Nage","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/608775404020544","repostId":"2668962129","repostType":2,"repost":{"id":"2668962129","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1789648373,"share":"https://ttm.financial/m/news/2668962129?lang=en_US&edition=fundamental","pubTime":"2026-09-17 20:32","market":"nz","language":"en","title":"Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962129","media":"Reuters","summary":"Niagen Bioscience names Martin Hendrix strategic adviser for corporate strategy, M&ANiagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a smal","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-09-17 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","NAGE":"Niagen Bioscience","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","XLV":"健康照护类股ETF-SPDR","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","RXL":"ProShares Ultra Health Care","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999015978.USD":"利安颠覆性创新基金A","IXJ":"全球医疗业ETF-iShares","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","FHLC":"Fidelity MSCI Health Care Index","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","AGNG":"Global X Aging Population ETF","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU2237443465.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","ABBV":"艾伯维公司","PPH":"VanEck Pharmaceutical ETF","IYH":"iShares U.S. Healthcare ETF","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","TRUH":"VanEck Healthcare TruSector ETF","PJP":"INVESCO PHARMACEUTICALS ETF","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","VHT":"Vanguard Health Care ETF","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL7b0CW9:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2668962129","content_text":"<a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n \n\n\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n \n\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n \n\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n \n\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"FHLC":0.6,"XLV":0.6,"PPH":0.6,"IXJ":0.6,"JDOC":0.6,"AGNG":0.6,"FTXH":0.6,"VHT":0.6,"IYH":0.6,"RXL":0.6,"ABBV":0.9,"GLAM":0.6,"MEDX":0.6,"NAGE":0.9,"PJP":0.6,"TRUH":0.6}},"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":608775404020544,"gmtCreate":1789653585918,"gmtModify":1789654069293,"author":{"id":"4136371379244552","authorId":"4136371379244552","name":"Yeocs818","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4136371379244552","authorIdStr":"4136371379244552"},"themes":[],"title":"","htmlText":"Good or bad for Nage","listText":"Good or bad for Nage","text":"Good or bad for Nage","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/608775404020544","repostId":"2668962129","repostType":2,"repost":{"id":"2668962129","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1789648373,"share":"https://ttm.financial/m/news/2668962129?lang=en_US&edition=fundamental","pubTime":"2026-09-17 20:32","market":"nz","language":"en","title":"Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962129","media":"Reuters","summary":"Niagen Bioscience names Martin Hendrix strategic adviser for corporate strategy, M&ANiagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a smal","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-09-17 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n </li>\n<li>\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n </li>\n<li>\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n </li>\n<li>\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","NAGE":"Niagen Bioscience","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","XLV":"健康照护类股ETF-SPDR","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","RXL":"ProShares Ultra Health Care","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999015978.USD":"利安颠覆性创新基金A","IXJ":"全球医疗业ETF-iShares","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","FHLC":"Fidelity MSCI Health Care Index","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","AGNG":"Global X Aging Population ETF","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU2237443465.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","ABBV":"艾伯维公司","PPH":"VanEck Pharmaceutical ETF","IYH":"iShares U.S. Healthcare ETF","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","TRUH":"VanEck Healthcare TruSector ETF","PJP":"INVESCO PHARMACEUTICALS ETF","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","VHT":"Vanguard Health Care ETF","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL7b0CW9:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2668962129","content_text":"<a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> names Martin Hendrix strategic adviser for corporate strategy, M&A\n \n\n\n Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.\n \n\n Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.\n \n\n Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.\n \n\n Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.\n \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"FHLC":0.6,"XLV":0.6,"PPH":0.6,"IXJ":0.6,"JDOC":0.6,"AGNG":0.6,"FTXH":0.6,"VHT":0.6,"IYH":0.6,"RXL":0.6,"ABBV":0.9,"GLAM":0.6,"MEDX":0.6,"NAGE":0.9,"PJP":0.6,"TRUH":0.6}},"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
